Literature DB >> 3815360

Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis.

B J Bowdon, W R Waud, G P Wheeler, R Hain, L Dansby, C Temple.   

Abstract

Several properties of four 1-deaza-7,8-dihydropteridines were compared with those of each other and with those of colchicine, nocodazole, podophyllotoxin, and vincristine. Compound NSC 370147 was more active than the other compounds of this type with respect to inhibition of proliferation of cultured L1210 cells and to increase of the mitotic index. On an equimolar basis it was more active than two of the 1-deaza-7,8-dihydropteridines, colchicine, and nocodazole and was comparable to podophyllotoxin and vincristine in inhibiting the polymerization of partially purified pig brain tubulin. All four of the 1-deaza-7,8-dihydropteridines caused decreases in the extent of binding of [3H]colchicine to partially purified tubulin and enhanced the binding of [3H]vincristine to the tubulin. Emphasis in further testing was placed upon NSC 370147, because it is easier to synthesize and is more stable than some of the other compounds of this type and because its greater solubility in water facilitates its formulation for therapeutic administration. Compound NSC 370147 inhibited competitively the binding of [3H]colchicine to purified tubulin and enhanced slightly the binding of [3H]vincristine to tubulin. It was also synergistic with vincristine in killing cultured L1210 cells and in increasing the life-spans of mice bearing P388 leukemia. It is suggested that it would be worthwhile to evaluate combinations of NSC 370147 and vincristine in tests with other experimental neoplasms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3815360

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.

Authors:  W R Waud; S D Harrison; C G Temple; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Cellular transport of CI-980.

Authors:  K E Hook; S A Przybranowski; W R Leopold
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  CI-980 in advanced melanoma and hormone refractory prostate cancer.

Authors:  C W Ryan; K L Shulman; J M Richards; J W Kugler; J A Sosman; R H Ansari; E E Vokes; N J Vogelzang
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

4.  Mode of action of tubulozoles against Plasmodium falciparum in vitro.

Authors:  A Dieckmann-Schuppert; R M Franklin
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  Extravasation injury potential of CI-980, a novel synthetic mitotic inhibitor.

Authors:  J R MacDonald; D G Pegg
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.

Authors:  R P Whitehead; J M Unger; L E Flaherty; J R Eckardt; S A Taylor; M S Didolkar; W Samlowski; V K Sondak
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

7.  A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.

Authors:  N T Sklarin; C D Lathia; L Benson; W R Grove; S Thomas; J Roca; A I Einzig; P H Wiernik
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

8.  Slow polymerization of Mycobacterium tuberculosis FtsZ.

Authors:  E L White; L J Ross; R C Reynolds; L E Seitz; G D Moore; D W Borhani
Journal:  J Bacteriol       Date:  2000-07       Impact factor: 3.490

9.  Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.

Authors:  S R Patel; M A Burgess; N E Papadopolous; G Sidhu; R Gray; C Plager; J Jenkins; R S Benjamin
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 10.  New small-molecule synthetic antimycobacterials.

Authors:  Lluis Ballell; Robert A Field; Ken Duncan; Robert J Young
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.